Ann Segeren
Neurology with Special Qualifications in Child Neurology · Stanford, CANPI 1447446794
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $114,683 of the $171,525 with a category attached, or 66.9%. 24 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 58.4% of the total. 2025 is the largest year on record at $42,652, more than ten times the $1,291 reported in 2019. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $476.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$100K
- Eisai Inc.$17K
- Aquestive Therapeutics, Inc.$17K
- Neurelis, Inc.$14K
- Supernus Pharmaceuticals, Inc.$8K
- Greenwich Biosciences, Inc.$5K
- plus $11K from 18 others
Across 53 payments — averaging $2132.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$51K
- Zogenix Inc.$36K
- UCB, Inc.$12K
- Neurocrine Biosciences, Inc.$10K
- UCB SA$4K
What the payments were for
- Consulting fees$31,32318%
- Speaking & faculty fees$114,68367%
- Travel & lodging$14,6669%
- Food & beverage$10,7636%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 110 | $100,113 |
| Eisai Inc. | 23 | $16,815 |
| Aquestive Therapeutics, Inc. | 42 | $16,676 |
| Neurelis, Inc. | 31 | $13,651 |
| Supernus Pharmaceuticals, Inc. | 14 | $7,645 |
| Greenwich Biosciences, Inc. | 53 | $5,198 |
| Neuropace, Inc. | 22 | $3,077 |
| Immedica Pharma US, Inc. | 7 | $2,938 |
| Neurocrine Biosciences, Inc. | 1 | $2,299 |
| H. Lundbeck A S | 2 | $1,079 |
| UCB, Inc. | 14 | $635 |
| Livanova USA, Inc. | 13 | $489 |
| Medtronic | 1 | $178 |
| Biocodex, Inc. | 2 | $112 |
| Sunovion Pharmaceuticals Inc. | 6 | $109 |
| SK Life Science, Inc. | 2 | $86 |
| Octapharma USA, Inc. | 1 | $83 |
| Novartis | 5 | $75 |
| Zogenix Inc. | 3 | $74 |
| Biomarin Pharmaceutical Inc. | 1 | $69 |
| Corium, LLC | 3 | $50 |
| NS Pharma, Inc. | 2 | $35 |
| Biogen | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$100,604
- SYMPAZAN$14,878
- Fycompa$10,322
- VALTOCO$8,390
- OXTELLAR XR$7,166
- Banzel$5,919
- ZTALMY$2,708
- RNS Neurostimulator Kit$2,159
- RNS System$222
- ACTIVA$178
- VNS Therapy$122
How this compares
$171,525 in reported general payments places this provider in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Other neurology with special qualifications in child neurology in Stanford
- Terence SangerStanford$73K
- Paul FisherStanford$9K
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
- Akash VirupakshaiahSan Francisco$94K
- Brittany PassiakSan Diego$90K
- Kevin ShapiroMadera$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.